CD8A and neoplasm: In one of the patients from each of the lead-in groups (A-2 and S-2), increases in CD19+ tumor-infiltrating B cells, CD68+ tumor-associated macrophages, CD4+ and CD8+ T cells (CD3+), as well as FOXP3+ regulatory T cells, were also observed.